


2018 FCDS Data Acquisition Manual and 2018 Abstracting Requirements


Florida Cancer Data System



University of Miami Miller
School of Medicine
Tax Building - Room 415
330 NW 10th Ave
Miami, Florida 33136
or
PO Box 014967 (D4-11)
Miami, Florida 33101

Data
Acquisition
Manual
2018

Phone: (305) 243-4400
Fax: (305) 243-4871




FCDS Annual Conference
Tampa, Florida
7/18/2018


Steven Peace, CTR


1

CDC & Florida DOH Attribution



“Funding for this conference was made possible (in part) by the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the US Government.”

 Centers for Disease
Control and Prevention




FCDS would also like to acknowledge the Florida Department of Health for its support of the Florida Cancer Data System, including the development, printing and distribution of materials for the 2018 FCDS Annual Conference and the 2018-2019 FCDS Webcast Series under state contract CODJU. The findings and conclusions in this series are those of the author(s) and do not necessarily represent the official position of the Florida Department of Health.

2

Presentation Outline

- 2018 FCDS Data Acquisition Manual
- 2018 STORE Manual
- Summary FCDS DAM Changes
- Focus on Specific Changes
- Using All Available Resources
- Abstracting 2018 Cases
- Questions



3

STORE Manual



4

2018 FCDS DAM




Summary of Changes

- Updated Section I – Guidelines for Reporting
- Clarifications on Specific Cancers and Reporting
 - LCIS is Reportable to FCDS (not reportable to NCDB)
 - Intraepithelial Neoplasm Grade III is Reportable to FCDS
 - AIN III
 - VIN III
 - VAIN III
 - PAIN III
 - LIN III
- Clarification on BIRADS 4 and BIRADS 5 and Date of Diagnosis – not based on imaging but on bx date
- Clarification - No Treatment versus Watch & Wait
- Clarification – When to Submit RQRS Abstracts
- 2018 Casefinding List (general and detail codes)
- Updated Data Request Section
- Updated Section II – Abstracting Instructions
- Added New Data Item Requirements by Section
 - CoC Accreditation
 - 3 New Grade Items
 - SS2018 Required for All Cases
 - AJCC Cancer Staging Items for 8th edition
 - SSDI Requirements
 - LVI – new codes added
 - Radiation Treatment Modality Field – only 1 required
- DO NOT USE C76.* Primary Site Codes – EVER
- Updated ICD-O-3 Requirements & Instructions
- Updated Grade Coding Instructions
- Updated Staging Requirements and Instructions

5

2018 FCDS DAM



Summary of Changes

- Appendix G – 2018 FCDS Record Layout
- Appendix H – 2018 FCDS Required SSDIs
- Appendix L – Updated Text Requirements
- Appendix O – Updated ICD-10-CM Casefinding
 - Short List
 - Detailed List
- Appendix P – 2018 Resources for Registrars
- Appendix Q – FCDS Profile Modification Form
- Appendix Q – DOH Letter on SSN Requirements
- Appendix R – ICD-O-3 Updates & Tables

6

Focus on Specific Changes New Data Items

- New Data Item Requirements by Section
- CoC Accreditation
- 3 New Grade Items
- SS2018 Required for All Cases
- AJCC Cancer Staging Items for 8th edition
- SSDI Requirements
- LVI – new codes added
- Radiation Treatment Modality Field – only 1 required

7

Focus on Specific Changes ICD-O-3 Updates

Guidelines for ICD-O-3 Update Implementation NAACCR, Inc.

North American Association of Central Registries, Inc.

GUIDELINES FOR ICD-O-3 HISTOLOGY CODE AND BEHAVIOR UPDATE IMPLEMENTATION Effective January 1, 2018

Prepared by:
NAACCR ICD-O-3 Update
Implementation Work Group

2018 ICD-O-3 Update to be used jointly with ICD-O-3, Hematopoietic and Lymphoid Neoplasm Database, and Solid Tumor Rules (MP/3)

December 1, 2017

Summary of changes covered in the 2018 ICD-O-3 Update:

The 2018 ICD-O-3 Update Guidelines includes comprehensive tables listing all changes to ICD-O-3 effective for cases diagnosed 1/1/2018 forward. The guidelines also provide background on the project and issues encountered during review of the WHO Classifications of Tumors. Issues not covered in the 2018 update include reportability of GIST and histology codes with terms that include the words "high grade neoplasia" or "high grade dysplasia" or "severe dysplasia" in digestive system sites.

On an international level, the need was recognized in 2010 for updating the morphology section to accurately code contemporary diagnoses described in the terms of the fourth editions of the World Health Organization's Classifications of Hematopoietic and Lymphoid Neoplasms, Tumors of the Central Nervous System, and Tumors of the Digestive System. In September 2011, the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) released the document *Updates to the International Classification of Diseases for Oncology, third edition (ICD-O-3)*.

Important information for lung cases: Per WHO 4th Ed Tumors of Lung: In 2011, a new IASLC/ATS/ERS classification of lung adenocarcinoma proposed significant changes to the 2004 WHO classification for resected tumors, including discontinuing the terms bronchioalveolar carcinoma (BAC).

Beginning with cases diagnosed 1/1/2018 forward, bronchioalveolar carcinoma (BAC) is no longer the preferred term.

Currently in ICD-O-3, when a topography (C code) is listed in parentheses next to the morphology term, it indicates morphology is most common to that site. It may occur in other sites as well. Many of the new codes, terms, and behaviors listed in this update are site-specific and do not apply to all sites. Applicable C codes will be noted next to the term in **bold font**. These site- and histology-specific combinations will not be added to the "Impossible combination" edit. However, if a site other than the one listed with the morphology code is assigned, the result will be an edit requiring review. This is Interfield Edit 25.

Focus on Specific Changes Cancer Staging and SSDIs

CANCER STAGING INFORMATION AND REQUIREMENTS BY DATE OF DIAGNOSIS

FCDS Cancer Staging Requirements follow the NPCR Stage Requirements by Year

State and National cancer staging requirements have changed over time. The focus of State and National cancer programs is monitoring cancer incidence over time. In order to support standardization and consistency in reporting stage of cancer at time of diagnosis, state and national cancer surveillance programs have often utilized a "summary staging" approach with stable anatomic staging criteria that includes both clinical data from imaging reports and medical procedures combined with pathological data gleaned from surgical resection of the primary tumor and regional lymph nodes. This is known as SEER Summary Stage. SEER Summary Stage has only gone through 2 revisions since it was instituted back in the mid-1970s. The latest edition is Summary Stage 2018 or SS2018. Summary Stage is required for all cases since 1981.

Facilities accredited by the Commission on Cancer tend to support changing clinical requirements for cancer staging – requiring frequent updates to the criteria used to determine cancer stage applying the AJCC Cancer Staging System that utilizes more detail in cancer staging data than does the state of Florida or the National Program of Cancer Registries. NPCR began to require AJCC Cancer Staging in 2016.

Continuity of staging requirements is essential for longitudinal cancer studies – but our programs recognize that changes in anatomic staging criteria have and continue to be modified over time. Furthermore, biomolecular and genetic tests to help qualify stage subgroups are being used more frequently with tests offering details for staging than ever before. In order to begin capturing these new tumor markers and other cancer-specific testing or prognostic-related laboratory tests, the United States created the Collaborative Stage Data Collection System including Site-Specific Factors to house these cancer-specific tests results and other clinical care and research oriented data items to expand 'staging'.

The Collaborative Stage Data Collection System was implemented for cases diagnosed 1/1/2004-12/31/2015 and provided algorithmic solutions to deriving standardized stage groupings based in multiple cancer staging systems including SS1977, SS2000, AJCC TNM 6th ed and AJCC TNM 7th ed.

The combined system of staging parameters was decommissioned and replaced by the originating staging systems being directly coded for SS2000 and AJCC TNM 7th ed. in 2016 and again updated in 2018 to provide updated anatomic and prognostic staging data items to meet current and future research needs.

SUMMARY STAGE 2018 (SS2018): Direct-Assignment of SEER Summary Stage using the SEER Summary Stage 2018 Manual is required for all cases diagnosed and reported to FCDS 1/1/2018 forward.

AJCC TNM CANCER STAGING, 8th EDITION: Direct-Assignment of clinical, pathological and post-treatment AJCC TNM Cancer Staging using the AJCC Cancer Staging Manual, 8th edition is required for all cases diagnosed/treated and reported to FCDS from 1/1/2018 forward.

9

Focus on Specific Changes Cancer Staging and SSDIs

2018 SEER Extent of Disease (SEER EOD): FCDS does not require or store any EOD fields at this time. FCDS has never required SEER EOD coding for any cases. Not in any version for any year of abstracting. We do not check for correctness or even valid codes. FCDS erases any EOD data received. If you decide to code these data, they are not verified, QC'd or used in any way. In addition, please note - before the 2018 SEER EOD was released; none of the previous versions of SEER EOD were supported, updated, or reflect anatomical staging of cancer for any of the years 2004-2016.

2018 Site-Specific Data Items (SSDI): An "SSDI" is a site-specific data item. "Site" in this instance is based on the primary site, the histologic type or histology of the tumor, the AJCC Chapter, Summary Stage Chapter and the EOD Schema. SSDIs were preceded by Collaborative Stage Data Collection System Site-Specific Factors or SSFs, which were first introduced in 2004 with CSv1, and went through major revisions in 2010 with Collaborative Stage v2 (CSv2). The CS SSFs were discontinued as of 12/31/2017.

SSDIs have their own data item name and number and can be collected for as many sites/chapters/schemas as needed. Each Site-Specific Data Item (SSDI) applies only to selected schemas. SSDI fields should be blank for schemas where they do not apply. Please refer to the SSDI Manual for SSDI definitions, rationale, and coding instructions. Comparison of SSDI to SSF is not advised due to differences in coding over time.

The SSDI and Grade Coding Manuals and Tools are available at <https://apps.naaccc.org/ssdi/list/>

FCDS requires only 58 of the 136 new SSDIs documented in the SSDI Manual. FCDS requires all SSDIs that are 'required for staging' or 'prognostically significant' according to AJCC, NPCR, and SEER reviews. Appendix H includes a complete listing of all FCDS-Required SSDIs. These are also listed in the FCDS Record Layout in Appendix G. Commission on Cancer accredited cancer programs require ALL SSDIs.

10

Focus on Specific Changes Cancer Staging and SSDIs

HISTORICAL STAGING SYSTEMS REFERENCE BY DIAGNOSIS YEAR

SEER SUMMARY STAGE 1977: Direct-Assignment of SEER Summary Stage using the SEER Summary Stage 1977 Manual was required for all cases abstracted and reported to FCDS before 1/1/2000.

SEER SUMMARY STAGE 2000: Direct-Assignment of SEER Summary Stage using the SEER Summary Stage 2000 Manual is required for all cases abstracted and reported to FCDS before 1/1/2018

AJCC TNM CANCER STAGING, 7TH EDITION: Direct-Assignment of clinical, pathological, and post-treatment AJCC TNM Cancer Staging using the AJCC Cancer Staging Manual, 7th edition is required for all cases diagnosed and reported to FCDS 1/1/2016 - 12/31/2017.

Required AJCC TNM 7th ed. Cancer Staging Items (Cancers diagnosed 1/1/2016 -12/21/2017)

Clinical T (NAACCR Item # 940)
Clinical N (NAACCR Item #950)
Clinical M (NAACCR Item #960)
Clinical Stage Group (NAACCR Item #970)
Clinical Stage (Prefix/Suffix) Descriptor (NAACCR Item #980)
TNM Clinical – Staged By (NAACCR Item#990)
Pathologic T (NAACCR Item #880)
Pathologic N (NAACCR Item #890)
Pathologic M (NAACCR Item #900)
Pathologic Stage Group (NAACCR Item #910)
Pathologic Stage (Prefix/Suffix) Descriptor (NAACCR Item #920)
TNM Pathologic – Staged By (NAACCR Item #930)
TNM Edition Number (NAACCR Item #1060)

11

Focus on Specific Changes Cancer Staging and SSDIs

COLLABORATIVE STAGE DATA COLLECTION SYSTEM (CSv2): Direct-Assignment of Core CS Data Items was required for all cases diagnosed 1/1/2004 and 12/31/2015 and seen at the facility for continuation of initial course of treatment or with evidence of recurrence or progression of cancer not previously reported to FCDS. This includes "non-analytic" cases with evidence of cancer. Some cases may still require the abstractor to use Collaborative Stage – please use the on-screen help to assign.

NOTE: Minimal Historical Cases (historical cancers with no evidence of the historical cancer – but having a new primary cancer diagnosis or undergoing treatment for a different primary cancer) are not required to have the Core CS Data Items coded. However, the minimal historical case will be required to have a SEER Summary Stage 2000 assigned and entered in the "historical grid" that is sent to FCDS.

Required Core CS Data Items (Cancers diagnosed 1/1/2004 thru 12/31/2015)

- *CS Tumor Size* (NAACCR Item #2800)
- *CS Extension* (NAACCR Item #2810)
- *CS Tumor Size/Ext Eval* (NAACCR Item #2820)
- *CS Lymph Nodes* (NAACCR Item #2830)
- *CS Reg Lymph Nodes Eval* (NAACCR Item #2840)
- *Regional Lymph Nodes Examined* (NAACCR Item #830)
- *Regional Lymph Nodes Positive* (NAACCR Item #820)
- *CS Mets at DX* (NAACCR Item #2850)
- *CS Mets Eval* (NAACCR Item #2860)

CS SITE-SPECIFIC FACTORS: CS Site-Specific Factors 1-25 were required for all cancers with an exception made for Minimal Historical Cases.

SEER EXTENT OF DISEASE: FCDS has never required SEER EOD coding for any cases. Not in any version for any year of abstracting. We do not check for correctness or even valid codes. FCDS erases any EOD data received. If you decide to code these data, they are not verified, QC'd or used in any way. Please note - before the 2018 SEER EOD was released; none of the previous versions of SEER EOD were supported, updated, or reflect anatomical staging of cancer for any of the years 2004-2016.

12

List of 2018 Required Manuals, Rules & Tools


APPENDIX F – REFERENCES AND RESOURCES FOR REGISTRARS – updated June 2018

2018 References and Resources for Cancer Registrars		
2018 REQUIRED References	Web Address For Source	Notes
2018 FCDS Data Acquisition Manual (DAM)	http://www.fda.med.va.gov/FCDS/DAM.shtml	Details cancer data reporting guidelines and confounding mechanisms for identifying reportable cancers
2018 Casefinding List of ICD-10-CM Required Codes	http://www.fda.med.va.gov/FCDS/DAM.shtml	ICD-10-CM for 2018 Casefinding - General Range and Individual Code Lists are available in the FCDS DAM
2018 MPH Rules - Solid Tumors MPH Rules PLUS Interactive Solid Tumors Database for Coding	https://seer.cancer.gov/tools/iaidb/mph/	On the home page click on "Information for Cancer Registrars", Hematopoietic & Lymphoid/Neoplasm Project
2018 MPH Rules - Heme-Lymph Neoplasm MPH Rules PLUS Interactive Heme-Lymph Database for Coding	https://seer.cancer.gov/tools/hemolymp/	On the home page click on "Information for Cancer Registrars", Hematopoietic & Lymphoid/Neoplasm Project
ICD-O-3 2010 and 2018 Updates and Coding Materials Also See 2018 FCDS DAM for ICD-O-3 Updates	https://seer.cancer.gov/icd-o-3/	On the home page click "Data Collection Tools", Errata and Classification"
Site-Specific Data Items Manual (SSDI Manual), SSDI Coding Instructions, and SSDI Coding Application	https://apps.seer.cancer.gov/ssdi/	
2018 Grade Manual, Grade Coding Instructions and Tables, and Grade Coding Application	https://apps.seer.cancer.gov/grade/	
APCC Cancer Staging Manual 19 th Edition (plus errata) Required for ALL 2018+ Cases	http://www.apccstage.com/medicare	
SEER Summary Staging Manual 2018 and any errata Required for ALL 2018+ Cases	http://seer.cancer.gov/tools/ssm/	
SEER*PSA for EOD - current version	https://staging.seer.cancer.gov/psa-software-1.0/	With pages with ALL 2018 Staging Items including SSDI
SEER *Rx - Interactive Drug Database	http://seer.cancer.gov/seer/tools/seer/rx/	A one-step lookup for coding oncology drug and regimen treatment categories in cancer registries
Collaborative Stage Data Collection System - v02.05 Part I Reference for Site-Specific Factor Coding ONLY	http://www.cancerstaging.org/stage/	Collaborative Stage Data Collection System is no longer supported or in use in the United States beginning 1/1/2016
Brain & CNS Tumor Reporting	http://www.cdc.gov/cancer/brain_reporting/	Brain Tumor Registry Reporting Materials
TEXT DOCUMENTATION	http://www.cancerregistryeducation.org/	Free Download - NCRA Informational Abstracts - Guidelines for Text Documentation by Cancer Site
Online Help For Abstracting Questions		
Ask a SEER Registrar/SEER Inquiry System	http://www.seer.cancer.gov/inquiries/contact.html	Type in a topic, search, and it will show you similar questions that other registrars have submitted along with the answers.
CAnswer Forum (Interactive Q&A Bulletin Board)	http://cancerbulletin.fda.gov/forum/	Type in a topic, search, and it will show you similar questions that other registrars have submitted along with the answers.

6/19/2018

13

Questions



14